Janssen-Cilag Australia has
welcomed the TGA approval of
Invokana (canagliflozin), an oral
once-daily sodium glucose cotransporter
2 (SGLT2) inhibitor, for
type 2 diabetes mellitus.
The new product is approved
for both monotherapy in lieu of
metformin, and as combination
therapy with other agents including
insulin, when these plus diet and
exercise don’t provide adequate
glycaemic control.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Oct 13
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.